Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System (FSGSALLAGE)
Treatment of Drug-resistant Adult and Pediatrc Primary Focal Segmental Glomerulosclerosis and Post -Transplant Recurrence Using the LIPOSORBER® LA-15 System
Sponsor: Kaneka Medical America LLC
This NA trial investigates Focal Segmental Glomerulosclerosis and is currently actively recruiting participants. Kaneka Medical America LLC leads this study, which shows 11 recorded versions since 2020 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
11 versions recorded-
Nov 2024 — Present [monthly]
Recruiting NA
-
Sep 2024 — Nov 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Apr 2023 — Jul 2024 [monthly]
Recruiting NA
-
May 2022 — Apr 2023 [monthly]
Recruiting NA
▶ Show 6 earlier versions
-
May 2021 — May 2022 [monthly]
Recruiting NA
-
Jan 2021 — May 2021 [monthly]
Recruiting NA
-
Apr 2020 — Jan 2021 [monthly]
Recruiting NA
-
Feb 2020 — Apr 2020 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jan 2020 — Feb 2020 [monthly]
Not Yet Recruiting NA
-
Sep 2019 — Jan 2020 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Kaneka Medical America LLC
For direct contact, visit the study record on ClinicalTrials.gov .